|
1. Cao W, Zhao C, Shen C, Wang Y. Cytokeratin 18, Alanine Aminotransferase, Platelets and Triglycerides Predict the Presence of Nonalcoholic Steatohepatitis. PloS One 2013; 8(12): e82092. 2. Amirkalali B, Poustchib H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran. Iran J Public Health 2014; 43(9): 1275-83. 3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatol 2012; 55(6): 2005-23. 4. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59(9): 1265-9. 5. Savadkoohi F, Hosseini Tabatabaei MT, Shahabi Nezhad S. The frequency of fatty liver in sonography of patients without liver diseases background and its correlation with blood cholesterol and triglyceride. Zahedan Univ Med Sci 2003; 5(2): 9-15. 6. Sohrabpour A, Rezvan H, Amini-Kafiabad S, Dayhim M, Merat S, Pourshams A. Prevalence of Nonalcoholic Steato hepatitis in Iran: A Population based Study. Middle East J Digestive Dis 2010; 2(1): 14-9. 7. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8(3): 521-33. 8. Koot GP, van der Baan-Slootweg OH, Bohte A E, Nederveen AJ, van Werven JR, Merkus MP, et al. Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity 2013; 21(3): 583-90. 9. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7(4): 350-7. 10. Yang HR. Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease. Korean J Pediatrics 2013; 56(2): 45-51. 11. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 2: 6-33. 12. Francque SM, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol 2012; 10(10): 1162-8. 13. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42(7): 503-8. 14. Mascolini M. FIB-4 Predicts Major Liver Complications and Death in HCV+ People Starting ART. 20th International AIDS Conference, 2014 July 20-25. Melbourne, Australia 15. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7(10): 1104-12 16. Yang HR, Kim HR, Kim MJ, Ko JS, Seo JK. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver. World J Gastroenterol 2012; 18(13): 1525-30. 17. Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12(1): 2. 18. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46(1): 32-6. 19. Shukla A, Kapileswar S, Gogtay N, Joshi A, Dhore P, Shah C, et al. Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with nonalcoholic fatty liver disease. Indian J Astroenterol 2015; 34(4): 281–5. 20. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33. 21. Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholicfatty liver disease. Hepatobiliary Pancreatic Dis Int 2012; 11(5): 513-20. 22. Feldstein AE. Wieckowska A, Lopez AR, Liu Yao C, Zein NN, McCullough AJ. Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology 2009; 50(4): 1072-8. 23. Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum Cytokeratin-18 Fragment Levels Are Useful Biomarkers for Nonalcoholic Steatohepatitis in Children. Am J Gastroenterol 2013; 108(9): 1526-31. 24. Verma S, Jensen D, Hart J, Mohanty SR. Pedictive value of ALT level for nonalcoholic steatohepatitis(NASH) and advance fibrosis in Non-alcoholic fatty liver disease (NAFLD). Liver International 2013; 33(9): 1398-405. 25. Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008; 6(11): 1249-54. 26. Jamali R. Non-Alcoholic Fatty Liver Disease: Diagnosis and Evaluation of Disease Severity. Thrita 2013; 2(4): 43-51. 27. Festi D, Schiumerini R, Marzi L, Di Biase AR,Mandolesi D, Montrone L, et al. Review article: the diagnosis of non‐alcoholic fatty liver disease–availability and accuracy of non‐invasive methods. Alimentary Pharmacol Therapeutics 2013; 37(4): 392-400. 28. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. 2012. The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6): 2005-23 29. Monteiro PA, Mota J, Silveira LS, Cayres SU, Antunes B, Fernandes RA, et al. Morphological and metabolic determinants of nonalcoholic fatty liver disease in obese youth: a pilot study. BMC Res Notes 2013; 6(1): 89. 30. Yilmaz Y. Systematic review: caspase‐cleaved fragments of cytokeratin 18–the promises and challenges of a biomarker for chronic liver disease. Alimentary Pharmacol Therapeutics 2009; 30(11-12): 1103-09. 31. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Seminars in liver disease. Hepatology 2008; 28(4): 386.
|
.png)
.png){kind=logo}
